Page last updated: 2024-11-05

4-propylphenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-Propylphenol is an organic compound with the formula CH3(CH2)3C6H4OH. It is a colorless liquid that is soluble in organic solvents. 4-Propylphenol is a natural product found in various plants and fungi. It is a key intermediate in the synthesis of pharmaceuticals, such as anti-inflammatory agents and antioxidants. 4-Propylphenol exhibits antimicrobial activity, inhibiting the growth of bacteria and fungi. This property makes it a potential candidate for the development of new antimicrobial drugs. Research into 4-propylphenol focuses on understanding its biological activities, including its antimicrobial effects, antioxidant properties, and potential therapeutic uses. Studies are exploring its potential as a natural pesticide and its role in plant defense mechanisms. Further research is necessary to fully understand the safety and efficacy of 4-propylphenol for various applications.'

4-propylphenol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12580
CHEMBL ID35297
CHEBI ID34434
SCHEMBL ID52058
SCHEMBL ID1375534
MeSH IDM0260733

Synonyms (55)

Synonym
BIDD:ER0185
phenol, p-propyl-,
einecs 211-446-2
brn 1363429
hydroxypropylbenzene, p-
nsc 65647
fema no. 3649
4-propylphenol
645-56-7
4-n-propylphenol
p-hydroxypropylbenzene
nsc-65647
phenol, 4-propyl-
nsc65647
phenol, p-propyl-
dihydrochavicol
1-hydroxy-4-n-propylbenzene
p-propylphenol
4-propylphenol, 99%
4-propylphenol, >=97%, fg
4-propylphenol, potassium
CHEMBL35297
chebi:34434 ,
4-propyl-phenol
P0698
A834809
tox21_302642
NCGC00256748-01
dtxsid9022100 ,
dtxcid402100
cas-645-56-7
h27vg833jy ,
unii-h27vg833jy
FT-0619321
AKOS009159302
propylphenol, p-
SCHEMBL52058
p-n-propylphenol
SCHEMBL1375534
W-104827
6-cyanohexylzincbromide
TS-01760
mfcd00002395
p-hydroxyphenylpropane
1-hydroxy-4-propylbenzene
fema 3649
p-propyl-phenol
1-(4-hydroxyphenyl)propane
F16572
Q27116062
EN300-64291
4-propylphenole
CS-W018327
SY036793
Z384970614
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
alkylbenzeneA monocyclic arene that is benzene substituted with one or more alkyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen nuclear receptor alphaHomo sapiens (human)Potency45.23370.000229.305416,493.5996AID743075; AID743079
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sulfotransferase 1A1 Rattus norvegicus (Norway rat)Km6.00005.00007.571410.0000AID39219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID282839Cytotoxicity against human CEM/VLB cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID282833Activity against caspase-mediated apoptosis in mouse L1210 cells at 0.1 mM2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID95754Protein interaction energy by using binding affinity towards human L-xylulose reductase enzyme2003Bioorganic & medicinal chemistry letters, Apr-17, Volume: 13, Issue:8
Structure-based design of inhibitors of human L-xylulose reductase modelled into the active site of the enzyme.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID39220Maximal velocity (Vmax) against Arylsulfotransferase (AST IV)2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Comparative molecular field analysis of substrates for an aryl sulfotransferase based on catalytic mechanism and protein homology modeling.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID282838Cytotoxicity against human CCRF-CEM cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID229377Ratio of kcat/Km determined for catalytic efficiency in sulfonation against AST IV2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Comparative molecular field analysis of substrates for an aryl sulfotransferase based on catalytic mechanism and protein homology modeling.
AID39219Apparent Michaelis constant (Km) against Arylsulfotransferase (AST IV)2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Comparative molecular field analysis of substrates for an aryl sulfotransferase based on catalytic mechanism and protein homology modeling.
AID282835Cytotoxicity against mouse L1210 cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's5 (62.50)29.6817
2010's2 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.12 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index43.22 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]